The present study demonstrated that clusterin protects against the pathophysiology of obesity and NAFLD by reducing body weight and fat mass, hepatic fat accumulation, and steatohepatitis. This evidence concerns the gene CLU and metabolic dysfunction-associated steatotic liver disease.